Skip to main content
. 2020 May 31;9(6):1362. doi: 10.3390/cells9061362

Figure 3.

Figure 3

Circulating tumor DNA (ctDNA) detection in plasma and matched PCa tissue samples using MS-ddPCR. (A–C) Ratio between methylated ctDNA and cfDNA copies for DOCK2 (A), HALPN3 (B), and FBXO30 (C) in plasma samples from healthy controls, BPH, localized PCa (PCa M0), and metastatic PCa patients (PCa M1). Each dot represents one analyzed sample. (D–F) Total number of copies of DOCK2 (D), HALPN3 (E), and FBXO30 (F) in BPH/AN tissue samples, and in matched PCa tissue samples and plasma samples from patients with localized PCa. Each dot represents one analyzed sample. (G–I) ROC curves comparing 19 BPH/AN and 41 PCa tissue samples for DOCK2 (G), HALPN3 (H), and FBXO30 methylation (I). p-values were calculated using Mann–Whitney tests. Horizontal bars indicate median values in each group. Healthy, healthy controls. BPH, benign prostatic hyperplasia. PCa, prostate cancer. M0, non-metastatic disease. M1, metastatic disease. ROC, receiver operating curve. AUC, area under the curve.